Advertisement
U.S. markets closed

Innate Pharma S.A. (IPH.PA)

Paris - Paris Delayed Price. Currency in EUR
1.4280+0.0120 (+0.84%)
As of 11:43AM CET. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
51,901
51,901
49,580
12,110
56,155
Cost of Revenue
-
-
-
-
3,042
Gross Profit
-
-
-
-
53,791
Operating Expense
64,570
64,570
66,005
59,937
55,076
Operating Income
-12,669
-12,669
-16,425
-47,827
1,079
Net Non Operating Interest Income Expense
2,537
2,537
258
15
223
Other Income Expense
2,562
2,562
-41,805
2,330
-2,131
Pretax Income
-7,570
-7,570
-57,972
-45,478
-829
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-7,570
-7,570
-58,103
-52,809
-63,984
Diluted NI Available to Com Stockholders
-7,570
-7,570
-58,103
-52,809
-63,984
Basic EPS
-0.79
-0.09
-0.73
-0.66
-0.81
Diluted EPS
-0.79
-0.09
-0.73
-0.66
-0.81
Basic Average Shares
79,923
84,111
79,640
79,543
78,935
Diluted Average Shares
79,923
84,111
79,640
79,543
78,935
Total Operating Income as Reported
-12,669
-12,669
-57,425
-47,825
1,079
Rent Expense Supplemental
-
-
-
-
1,702
Total Expenses
64,570
64,570
66,005
59,937
55,076
Net Income from Continuing & Discontinued Operation
-7,570
-7,570
-58,103
-52,809
-63,984
Normalized Income
-10,132
-10,132
-16,167
-47,808
1,302
Interest Income
3,177
3,177
546
327
564
Interest Expense
640
640
288
312
341
Net Interest Income
2,537
2,537
258
15
223
EBIT
-6,930
-6,930
-57,684
-45,166
-488
EBITDA
-1,839
-1,839
-12,279
-40,570
56,309
Reconciled Cost of Revenue
-
-
-
-
3,042
Reconciled Depreciation
5,091
5,091
45,405
4,596
56,797
Net Income from Continuing Operation Net Minority Interest
-7,570
-7,570
-57,972
-45,478
-829
Total Unusual Items Excluding Goodwill
2,562
2,562
-41,805
2,330
-2,131
Total Unusual Items
2,562
2,562
-41,805
2,330
-2,131
Normalized EBITDA
-4,401
-4,401
29,526
-42,900
58,440
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0